For 26 days, study participants throughout 10 countries either received J&J’s drug candidate, JNJ-1802, or placebo doses daily. The phase 2 study found the therapy, which is designed to target circulating dengue serotypes, reduced antiviral activity and was safe and effective, according to a news release.
About 4 billion people worldwide live in areas at risk for dengue, according to the CDC. There’s a dengue vaccine available, but no antivirals for the virus are approved. J&J did not disclose when it might submit its experimental drug for regulatory approval.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
